A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
Public ClinicalTrials.gov record NCT03778957. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma
Study identification
- NCT ID
- NCT03778957
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 724 participants
Conditions and interventions
Conditions
Interventions
- Durvalumab Drug
- Bevacizumab Drug
- Placebo Other
- Transarterial Chemoembolization (TACE) Procedure
Drug · Other · Procedure
Eligibility (public fields only)
- Age range
- 18 Years to 110 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2018 (Actual)
- Primary completion
- Sep 11, 2023 (Actual)
- Completion
- Aug 31, 2026 (Estimated)
- Last update posted
- Jul 15, 2026
2018 – 2026
United States locations
- U.S. sites
- 24
- U.S. states
- 18
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Costa Mesa | California | 92627 | — |
| Research Site | La Jolla | California | 92093-0698 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Jacksonville | Florida | 32224 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research Site | Honolulu | Hawaii | 96819 | — |
| Research Site | Chicago | Illinois | 60612 | — |
| Research Site | Shreveport | Louisiana | 71103 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Rochester | Minnesota | 55905-0001 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Stony Brook | New York | 11794 | — |
| Research Site | Charlotte | North Carolina | 28204 | — |
| Research Site | Cleveland | Ohio | 44106 | — |
| Research Site | Portland | Oregon | 97213 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Sioux Falls | South Dakota | 57105 | — |
| Research Site | Memphis | Tennessee | 38104 | — |
| Research Site | Dallas | Texas | 75216 | — |
| Research Site | Dallas | Texas | 75235 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Houston | Texas | 77090 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 142 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03778957, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 15, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03778957 live on ClinicalTrials.gov.